Your browser doesn't support javascript.
loading
Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study.
Viapiana, O; Idolazzi, L; Fassio, A; Orsolini, G; Rossini, M; Adami, G; Bertoldo, F; Gatti, D.
Afiliación
  • Viapiana O; Rheumatology Unit, Department of Medicine, University of Verona, p.le L Scuro 2, 37100, Verona, Italy.
  • Idolazzi L; Rheumatology Unit, Department of Medicine, University of Verona, p.le L Scuro 2, 37100, Verona, Italy. luca.idolazzi@univr.it.
  • Fassio A; Rheumatology Unit, Department of Medicine, University of Verona, p.le L Scuro 2, 37100, Verona, Italy.
  • Orsolini G; Rheumatology Unit, Department of Medicine, University of Verona, p.le L Scuro 2, 37100, Verona, Italy.
  • Rossini M; Rheumatology Unit, Department of Medicine, University of Verona, p.le L Scuro 2, 37100, Verona, Italy.
  • Adami G; Rheumatology Unit, Department of Medicine, University of Verona, p.le L Scuro 2, 37100, Verona, Italy.
  • Bertoldo F; Internal Medicine, Department of Medicine, University of Verona, p.le L Scuro 2, 37100, Verona, Italy.
  • Gatti D; Rheumatology Unit, Department of Medicine, University of Verona, p.le L Scuro 2, 37100, Verona, Italy.
Calcif Tissue Int ; 100(4): 341-347, 2017 04.
Article en En | MEDLINE | ID: mdl-28130572
The aim of this study was to assess the long-term efficacy and safety of i.v. neridronate in the treatment of osteogenesis imperfecta (OI). One hundred and fourteen patients affected by OI were included in the study. Neridronate was administered by i.v. infusion at the dosage of 2 mg/kg, up to a maximum of 100 mg at three-month intervals for 3 years. Dual X-ray absorptiometry of the lumbar spine, hip, and ultradistal and proximal radius were evaluated every 6 months. Blood calcium, phosphate, albumin, fasting urinary calcium/creatinine ratio, total serum alkaline phosphatase, and bone alkaline phosphatase were obtained at baseline and every 3 months. The mean lumbar spine and total hip BMD significantly increased from baseline to any time point (p < 0.001). The mean ultradistal radius BMD significantly increased from baseline only at month 18 (p = 0.026), 30 (p = 0.046), and 36 (p = 0.013), respectively. The mean proximal radius BMD did not change during the whole observation. The levels of bone turnover markers significantly decreased from baseline to any post-baseline observation time. The study was not able to find any statistically significant effect on fracture risk (p = 0.185). The percentage of patients with fractures was unaltered during treatment as compared to the 3-year period before treatment. The most common AEs were fragility fractures, back pain, arthralgia, fever, and joint sprain. An acute phase reaction was reported in 26 (22.8%) patients. None of the reported SAEs were considered as treatment-related. Long-term treatment with i.v. neridronate has positive effects on BMD and bone turnover markers with a good safety profile, although no significant effect on the risk of fracture was observed.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteogénesis Imperfecta / Densidad Ósea / Difosfonatos Tipo de estudio: Observational_studies Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Calcif Tissue Int Año: 2017 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteogénesis Imperfecta / Densidad Ósea / Difosfonatos Tipo de estudio: Observational_studies Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Calcif Tissue Int Año: 2017 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos